Pharmacology and Analytical Facility - HPLC and Mass Spectrometry Facility This facility provides access to sophisticated HPLC, ultra high performance liquid chromatographic and mass spectrometry instruments. In this facility, analytical assay methodologies can be developed and validated using UPLC/HPLC equipment with a broad array of quantitative detection systems (e.g. UV, photodiode array, fluorescence, radiometric, light scattering, electrochemical). Current mass spectrometry instruments include a simple single quad LC/MS instrument for use in molecular weight determinations as well as more complex tandem mass spectrometers (7 total), including a time-of-flight instrument for more intricate drug metabolism studies and experiments requiring accurate mass weight measurements. In addition, a GC/MS instrument is available for separation and quantitation of volatile compounds. Recently added were automated solid phase and liquid extraction platforms capable of isolating multiple analytes of interest (drugs, macromolecules, and protein drug targets) from complex biomatrices (blood, plasma, normal organ tissues, and tumors). These extraction systems have improved both extraction efficiency and throughput in analytical sample preparation. The laboratory has supported experiments in chemical synthesis, drug library screening, medicinal chemistry, drug discovery and development, drug metabolism, drug target identification, drug metabolism, drug tissue biodistribution, systemic pharmacokinetics, drug production solubility and stability, formulation, and tumor biochemistry. The HPLC/Mass Spectrometry Facility sampled analysis increased over 340% since 1999 and is now analyzing more than 33,000 samples per year serving over 52 faculty members who are members of 21 CCSG Programs;90% of the users have peer-reviewed funding. The current source of funding is 48.4% CCSG, and 51.6% user fees. This state of the art facility is located at a newly renovated El Rio campus located approximately 1 mile from the main campus. This location is a 7250 sq. ft. facility that houses 4 faculty members and 21 support staff as well as 25 full UPLC/HPLC systems. In addition to the advanced analytical facility the combined program faculty have in excess of 60 years of experience in analytical chemistry, analytical method development and validation, isolation technologies, pharmacology, drug metabolism, and pharmacokinetic/pharmacodynamics. They act as an invaluable resource in experimental design, development and implementation to the user faculty who often lack the specific training to conduct experiments requiring quantitative analytical chemistry and pharmacology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-36
Application #
8310856
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
36
Fiscal Year
2011
Total Cost
$448,337
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Chang, George J (2018) Leveraging Data, the Next Big Advance for Quality Improvement in Colorectal Cancer. Dis Colon Rectum 61:415-416
Rauch, Gaiane M; Kuerer, Henry M; Adrada, Beatriz et al. (2018) Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints. Ann Surg Oncol 25:1953-1960
Peng, Bo; Wang, Gao; Ma, Jun et al. (2018) SoS Notebook: an interactive multi-language data analysis environment. Bioinformatics 34:3768-3770
Ariza-Heredia, Ella J; Chemaly, Roy F; Shahani, Lokesh R et al. (2018) Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study. Transpl Int 31:639-648
Kraft, Ira L; Akshintala, Srivandana; Zhu, Yuelin et al. (2018) Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. Clin Cancer Res 24:753-765
Rozovski, Uri; Harris, David M; Li, Ping et al. (2018) STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget 9:21268-21280
DeFilipp, Zachariah; Peled, Jonathan U; Li, Shuli et al. (2018) Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv 2:745-753
Wang, Jian; Shete, Sanjay (2018) Estimation of indirect effect when the mediator is a censored variable. Stat Methods Med Res 27:3010-3025
Chambers, Mark S; Rugo, Hope S; Litton, Jennifer K et al. (2018) Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer. J Am Dent Assoc 149:291-298
Echeverria, Gloria V; Powell, Emily; Seth, Sahil et al. (2018) High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. Nat Commun 9:5079

Showing the most recent 10 out of 12418 publications